Share This Page
Drug Price Trends for NEULASTA
✉ Email this page to a colleague
Best Wholesale Price for NEULASTA
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Unit | Dates | Price Type |
|---|---|---|---|---|---|---|---|---|
| NEULASTA ON PRO 6MG/0.6ML INJ | Amgen USA, Inc. | 55513-0192-01 | 0.6ML | 4020.10 | 6700.16667 | ML | 2022-06-23 - 2026-01-31 | FSS |
| NEULASTA 6MG/0.6ML INJ SINGLE-USE SYRINGE | Amgen USA, Inc. | 55513-0190-01 | 1 | 2384.80 | 2384.80000 | EACH | 2024-01-01 - 2026-01-31 | Big4 |
| NEULASTA 6MG/0.6ML INJ SINGLE-USE SYRINGE | Amgen USA, Inc. | 55513-0190-01 | 1 | 4146.87 | 4146.87000 | EACH | 2021-02-01 - 2026-01-31 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Unit | >Dates | >Price Type |
Market Analysis and Price Projections for NEULASTA (Pegfilgrastim)
Introduction
NEULASTA (pegfilgrastim) is a long-acting granulocyte colony-stimulating factor (G-CSF) used primarily to reduce the incidence of febrile neutropenia in patients undergoing chemotherapy. Developed by Amgen, NEULASTA has secured a significant market share within the hematology and oncology therapeutic sectors. As the global demand for supportive cancer care grows, analyzing NEULASTA’s market landscape and projecting its pricing trends are vital for stakeholders, including investors, healthcare providers, and policy developers.
Market Overview
Global Market Size
The global G-CSF market, including NEULASTA, was valued at approximately USD 4.3 billion in 2022, with projections reaching USD 6.8 billion by 2030, growing at a CAGR of 6.5% (2023–2030) [1]. This growth correlates with increasing cancer incidence, expanding chemotherapy indications, and the shift toward supportive care remedies that improve patient outcomes and quality of life.
Key Market Drivers
- Rising Cancer Incidence: The World Health Organization reports a global increase in cancer cases, with an estimated 19.3 million new cases in 2020, anticipated to double by 2040. This trend directly fuels demand for supportive treatments like NEULASTA.
- Advancements in Oncology Treatment: More aggressive chemotherapy protocols require effective neutropenia management, positioning NEULASTA as a preferred option due to its once-per-cycle dosing.
- Expanded Indications: NEULASTA's approval for indications beyond chemotherapy-induced neutropenia, including stem cell mobilization, broadens its market scope.
- Competitive Landscape: Entry of biosimilars and generics acts as both a challenge and an opportunity, influencing pricing strategies and market dynamics.
Competitive Environment
Amgen’s NEULASTA holds an approximate 70% market share within the G-CSF niche, supported by its patent protections, established manufacturing capacity, and clinical efficacy data [2]. Biosimilars like Sandoz’s Ziextenzo and Fresenius Kabi’s filgrastim-sndz are entering the scene, potentially exerting downward pressure on prices starting in 2024 as patent exclusivities expire.
Regulatory and Reimbursement Factors
Reimbursement policies significantly influence NEULASTA’s market penetration. High-cost therapies often encounter reimbursement hurdles, but government programs, including Medicare and Medicaid in the US, support supportive care drugs for approved indications. Globally, reimbursement landscape varies, with stricter coverage in lower-income regions possibly limiting market growth.
Price Analysis
Current Pricing Landscape
- US Market: The average wholesale price (AWP) for NEULASTA is approximately USD 4,500 per single-use, prefilled syringe, with patient out-of-pocket costs varying depending on insurance coverage (Healthcare Bluebook, 2023).
- International Variations: In Europe and Asia, prices are generally lower, averaging USD 3,000–4,000, influenced by healthcare policies and negotiated drug prices [3].
Factors Affecting Pricing
- Patent Status: Patents for NEULASTA expired in the US and Europe in 2024, paving the way for biosimilar competition, which is expected to lead to price reductions.
- Biosimilar Entry: The anticipated biosimilar options could see prices drop by 20–40% upon market entry. Historically, biosimilar competition in oncology drugs tends to reduce the incumbent’s price by 25% on average [4].
- Manufacturing and Supply Chain Costs: As a biologic, NEULASTA’s production involves complex processes with high upfront costs. Advances in manufacturing efficiencies could temper future price increases.
Market Price Projections
Pre-Biosimilar Era (2023–2024)
Prior to biosimilar entry, NEULASTA’s pricing is expected to remain relatively stable, supported by the drug’s proven efficacy and brand loyalty. However, in light of upcoming patent expirations, slight downward pressure might emerge, anticipating a 5–10% decrease in retail prices by late 2024.
Post-Biosimilar Entry (2025–2030)
Following biosimilar approvals and market penetration, NEULASTA’s price could decline significantly. Conservative estimates suggest:
- 2025–2027: a 15–25% price reduction across major markets.
- 2028–2030: stabilized prices with biosimilars capturing approximately 30–50% of the market share, leading to further price erosion of up to 40% compared to 2024 levels.
Revenue Projections
Despite potential price reductions, increased patient access and expanded indications are expected to maintain NEULASTA’s revenue streams. Revenue growth will depend on:
- Biosimilar adoption rates.
- Geographic expansion into emerging markets.
- Reimbursement landscape adjustments.
By 2028, the global NEULASTA market valuation could stabilize at approximately USD 2.4–3.0 billion, representing a compound annual growth rate of around 3–4%, factoring in volume increases offsetting price declines [1].
Strategic Implications for Stakeholders
- Pharmaceutical Companies: Investment in biosimilar development offers immediate cost advantages but entails regulatory and market-entry risks.
- Healthcare Providers: Adoption strategies will need to balance efficacy, cost, and reimbursement considerations.
- Policymakers: Price regulation and reimbursement policies will significantly influence future market dynamics and access levels.
Conclusion
The NEULASTA market exhibits resilient growth driven by expanding cancer therapies, but impending patent expirations and biosimilar competition will considerably reshape its pricing and market share. Stakeholders must closely monitor biosimilar developments and policy changes to optimize pricing strategies and ensure sustainable access.
Key Takeaways
- The global G-CSF market is projected to grow at a CAGR over 6%, with NEULASTA maintaining a dominant position until biosimilar competition intensifies from 2024 onward.
- Pre-biosimilar prices remain stable, with minor reductions expected in preparation for patent expirations.
- Biosimilar entry is likely to trigger a 20–40% reduction in NEULASTA’s retail price, influencing revenue projections and market share.
- Expanded indications and geographic penetration will partly offset pricing pressures, supporting steady revenue streams.
- Stakeholders should proactively adapt to regulatory shifts, reimbursement alterations, and biosimilar market entry to maximize value.
FAQs
1. When will biosimilars for NEULASTA enter the market, and how will they impact pricing?
Biosimilars are expected to gain approval starting in 2024, with market penetration likely within 1–2 years post-approval. Their entry typically results in a 20–40% price reduction due to increased competition [4].
2. How does NEULASTA compare to its competitors in terms of efficacy and cost?
NEULASTA demonstrates high efficacy in reducing febrile neutropenia and offers a convenient once-per-cycle dosing regimen. While more expensive than some biosimilars or off-label alternatives, its longstanding clinical track record reinforces its premium positioning until biosimilar competition influences pricing.
3. What factors influence the pricing strategies of NEULASTA in different countries?
Pricing strategies vary based on patent status, healthcare reimbursement policies, negotiated discounts, and market competition in each region. Developed markets generally support higher prices due to better reimbursement frameworks, while emerging markets negotiate lower prices for expanded access.
4. What innovations could influence the future of NEULASTA’s market share?
Advances in biosimilar manufacturing, personalized oncology treatments, and improved supportive care protocols could alter market dynamics. Additionally, new therapies that reduce neutropenia risk may challenge NEULASTA’s dominance.
5. How can stakeholders prepare for the upcoming biosimilar competition?
Stakeholders should monitor regulatory developments, engage in pricing negotiations, diversify portfolio offerings, and consider value-based reimbursement models to mitigate risks associated with biosimilar entry.
References
[1] Market Research Future. (2022). Granulocyte Colony-Stimulating Factors Market Size & Trends.
[2] Amgen Inc. (2023). NEULASTA Product Information.
[3] IQVIA. (2022). Global Oncology Drug Pricing Review.
[4] Perri, R. et al. (2021). Impact of Biosimilar Competition on Oncology Drug Pricing. Journal of Clinical Oncology.
More… ↓
